CHARLES RIVER LABORATORIES INTERNATIONAL, INC. acquires ChanTest

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. acquired ChanTest for $59.3 million (including $0.3 million in contingent consideration), a transaction completed in October 2014, structured as all cash.

ChanTest operates in Discovery and Safety Assessment (DSA) — Early Discovery, is based in United States. ChanTest was a leading provider of ion channel testing services to the pharmaceutical and biotech industry, augmenting Charles River's early discovery capabilities.

In October 2014, the Company acquired ChanTest, a leading provider of ion channel testing services to the pharmaceutical and biotech industry. The acquisition augments the Company's early discovery capabilities and enhances the Company's ability to support clients' target discovery and lead optimization efforts. The preliminary purchase price of the acquisition was $59.3 million.

Early Discovery business, DSA segment

In October 2014, the Company acquired ChanTest, a leading provider of ion channel testing services to the pharmaceutical and biotech industry. The acquisition augments the Company's early discovery capabilities and enhances the Company's ability to support clients' target discovery and lead optimization efforts. The preliminary purchase price of the acquisition was $59.3 million.Charles River FY2014 10-K, Business Acquisitions note

Advisory firms were not disclosed for this transaction.

You're subscribed.

Thanks for signing up.